Goal 2: Reduce Human Disease

How to organize artificial pulsatile propelling of blood maintaining the balanced circulation?

Venous pressure, being very low, distends (deforms) the ventricle - but due to elastic or viscous law of deformation? Elastic deformation depends on stress (pressure) only and the viscous one - on stress and time. When pressures are low you can't get large distention due to stress only (time-independent) unlike the case when you apply low stress and long time interval. If we want to use venous pressure as one of regulators ...more »

Submitted by (@yuri.astrakhan)

Voting

-9 net votes
2 up votes
11 down votes
Active

Goal 2: Reduce Human Disease

Pathobiology of Lung Fibrosis

End organ fibrosis accounts for up to 45% of deaths in developed countries. In particular, lung fibrosis is a devastating disease with poor prognosis. Despite development of two new drugs, their efficacy is still limited, highlighting the need to better understand the pathobiology that accounts for fibrotic disease progression in the presence and absence of acute exacerbation or infectious drivers.

Submitted by (@bmoore)

Voting

19 net votes
30 up votes
11 down votes
Active

Goal 2: Reduce Human Disease

National AICD and resynchronization therapy prospective registry

Emerging data suggest underutilization and variation of care in heart failure patients with ICD defibrillator therapy. Furthermore, there is a lack of data about those who benefit and those who will not benefit, including the role of gender, age and CHF morphology (phenotype).

 

creation of reliable and validated data entered into a registry with cases and controls

Submitted by (@nhlbiforumadministrator1)

Voting

-9 net votes
3 up votes
12 down votes
Active

Goal 3: Advance Translational Research

Facilitation of adoption of evidence-based guidelines in clinical practice for CVD risk factor identification and treatment

Multiple factors contribute to the high mortality from heart and vascular diseases in our population, most prominently genetics, patient behavior, care access, and care quality. Historically, interventions have targeted patient behaviors. Though access remains a problem, those who do receive care may not be getting the best of care based on the evidence. A focus on increasing practitioner adoption of evidence-based ...more »

Submitted by (@rubybenjamingarner)

Voting

1 net vote
3 up votes
2 down votes
Active

Goal 2: Reduce Human Disease

Open up NCATS

The NCATS program for drug repurposing is currently only open to drugs submitted by industry (read, big Pharma). We have had the experience of working to repurpose a generic drug not on their list, and despite great Preliminary data, we could not. This program is a great idea, but needs to be opened to any company and any drug for which solid data backing efficacy and market can be applied. Why do we only want to enhance ...more »

Submitted by (@wjones7)

Voting

-5 net votes
5 up votes
10 down votes
Active

Goal 3: Advance Translational Research

Novel Cell Apheresis Technologies to Treat Hematologic Diseases

Current FDA approved apheresis technology uses elutriation/centrifugation or filtration separation techniques to remove pathologic cellular and/or plasma elements. Currently these techniques are non-specific, limited by inefficient removal kinetics and often require considerable blood product exposure. Despite tremendous improvement in our understanding of the pathophysiology of a variety of disease, our ability to ...more »

Submitted by (@ewong0)

Voting

118 net votes
139 up votes
21 down votes
Active

Goal 2: Reduce Human Disease

The role of Extracorporeal Photopheresis (ECP) in the prevention and treatment of rejection of heart and lung transplants

According to the ISHLT, more than 4,000 patients undergo a heart transplant each year, and almost 4,000 receive single or double lung transplants. Their prognosis depends heavily on the avoidance of rejection, which claims the majority of their lives. For heart transplant recipients, the median survival is 11 years, while for lung transplant recipients, it is approximately 5 years. The current most common anti-rejection ...more »

Submitted by (@mmarques)

Voting

80 net votes
102 up votes
22 down votes
Active